Dr. Ritu Lal, Ph.D., M.S. is the CEO and co-founder of GEn1E Lifesciences. She is a leader in Pharmaceutical R&D with 20+ years of experience in Biotech/Pharma companies. She has taken compounds from discovery to regulatory approval and has filed 15+ IND applications with the FDA in disease areas of neurology, inflammation, virology, pain and oncology. Two of these compounds have received New Drug Application (NDA) approvals from the FDA and Ministry of Health and Welfare, Japan (Kaletra® for the treatment of HIV and Horizant® (Regnite® in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN)). She has a doctorate in Pharmaceutical Sciences from the University of Maryland and a Master’s degree in Pharmacology from the University of Arizona. She has over 60 publications, book chapters and presentations. She is also a graduate of the Stanford University Graduate School of Business’ Master’s Degree in Management program.
WENDY LUO, M.S., VP RESEARCH
Wendy Luo, M.S., is our Head of Research. With 25 years of experience in Pharma/Biotech companies, her role is to lead GEn1E Lifesciences’ efforts toward the goal of curing inflammation and age-related diseases. Her most recent working experience was Sr. Director at CohBar Inc, focusing on product candidates for the potential treatment of diseases of aging, including NASH, obesity and Type 2 diabetes. Previously, she was Sr. Director of Bioanalytical & QC at XenoPort Inc. In this role, she contributed to drug discovery, preclinical and clinical development across the XenoPort pipeline, including two New Drug Applications (NDAs) and four programs which entered clinical trials. Her experience prior to XenoPort includes technical positions in Applied Biosystems and Allergan Inc. Ms. Luo received her M.S. in Chemistry from Arizona State University and her B.S. degree from Fudan University School of Pharmacy.
Clint Webb, J.D. COO
Clint Webb is the co-founder of GEn1E Lifesciences. He has 20 years of experience in Pharma/Biotech/Medical Device in operational and legal leadership. His work experience includes positions with Morrison & Foerster, LLP, Genelabs Technologies, Ilypsa, OXiGENE and Symyx Technologies. Within this family of companies, two compounds received regulatory approvals – Bixalomer® for the treatment of hyperphosphatemia and Veltassa® for the treatment of hyperkalemia. He focuses on operations, finance, licensing, R&D collaboration, IP and portfolio management.
Contact us today to learn more about GEn1E Lifesciences